WuXi XDC’s Post

Check out the latest issue of Pharma Industrial India with Molly Weaver, PhD and Paul Rutter, MD on page 37 https://hubs.li/Q02Zkdrq0 Learn how the Apiject Platform helps grow your market share. • Affordability for LMICs • Regulatory in Global Markets • Safety/Efficacy in Delivery • Storage/Distribution for LMIC • Simulation for Device Performance • Goals for Expanding Access in LMICs #LMIC #globalmarket #globalhealth #drugdelivery #injectable Russell (Bo) Kowalczyk PJ Kim Joseph Wojcik

📢 Switzerland’s Basel region is crowned Europe’s top spot for launching drug device companies! 🏆💊 Thanks to cutting-edge research, precision manufacturing, and skilled talent, Basel leads the way in med-tech innovation. 🌍 #Pharma #Innovation #TechTuesday ✨: https://ow.ly/EnU650UGtxs

With the U.S. Congress reviewing the Biosecure Act, concerns over clinical and commercial supply chains are intensifying, particularly as reshoring manufacturing gains momentum. Syner-G BioPharma Group supports these changes with: - Supplier Selection: Vetting labs and CDMOs - Tech Transfers: Seamless transfer plans - Skilled Expertise: Method development and formulation - Local Presence: “Person-in-plant” support in the U.S. and India Let’s connect to discuss streamlining your operations in response to these shifts: https://lnkd.in/eRAW_ewD #BiosecureAct #ClinicalSupplyChains #TechTransfer

Citing national security threats from foreign adversary corporations, this law prohibits government agencies and entities that receive federal dollars from exploiting biotechnology linked to those companies, especially when it comes to multiomic data (e.g., genomic information). The Department of Defense (DOD) and the Office of Management and Budget (OMB) are required to compile a list of corporations that are barred, which must include five designated firms. For a maximum of one and a half years, limited waivers may be given. The Office of the Director of National Intelligence is also required to evaluate the hazards associated with biotechnology and foreign enemies' data acquisition. Reference: https://lnkd.in/gMfqqvHk

Smart Pills Market worth $1.1 billion by 2028 Download PDF Brochure:-https://lnkd.in/dTGMcGrz The global smart Pills market growth is projected to reach USD 1.1 billion by 2028 from USD 0.6 billion in 2023, at a CAGR of 11.8% during the forecast period. Global Smart Pills Market Dynamics ✅ Driver: Rising demand for non-invasive diagnostic and monitoring devices ✅ Restraint: High cost associated with smart pills ✅ Opportunity: Growing demand for advance drug delivery system ✅ Challenge: Implications with patient privacy 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Chongqing Jinshan Science & Technology (group) Co., Ltd. RF Medical Co., Ltd. etectRx BodyCAP CapsoVision, Inc., Medtronic Check-Cap Ltd. IntroMedic Co.,Ltd AnX Robotica Corp. Olympus Corporation OTSUKA AMERICA PHARMACEUTICAL INC #SmartPills #DigitalHealth #MedicalInnovation #HealthcareTechnology #MedTech

The proposed Biosecure Act could transform the pharmaceutical industry, prioritizing resilient, localized supply chains and addressing today’s global challenges. In many ways, it’s a call to rethink how we innovate, manufacture, and deliver impactful therapies. At SmaBio Labs, we see this as an opportunity to empower our partners with agile solutions, streamlined operations, and cutting-edge capabilities—all while keeping innovation at the forefront. Reshoring manufacturing isn’t just a shift in process; it’s a chance to build a more adaptable, efficient, and future-ready industry. As we prepare to navigate these changes together, we’re excited about the possibilities for collaboration, transformation, and progress. What opportunities or challenges do you see with the Biosecure Act? Let’s connect and explore how we can shape the future of healthcare, together. #ShapingPharma #BiosecureAct #ResilientSupplyChains #FutureReadyHealthcare

Ocular Drug Delivery Technology Market Detailed Analysis 2024: Market Size, Future Prospects, and Industry Trends https://lnkd.in/eW-2j5Q8 #marketanalysis #marketresearch #marketresearchreports #businessintelligence

Modern drug delivery systems, such as nanoparticles, liposomes, and targeted delivery mechanisms, present unique regulatory challenges. These innovative technologies often lack established regulatory frameworks, making it difficult to ensure consistent safety and efficacy standards. Regulators must adapt to rapidly evolving scientific advancements, requiring comprehensive evaluation methods and updated guidelines. Additionally, the complexity of these systems demands rigorous quality control and Good Manufacturing Practice (GMP) inspections to prevent contamination and ensure product integrity. Balancing innovation with stringent regulatory oversight is crucial to protect public health while fostering the development of cutting-edge therapies. #kingstonuniversitylondon #regulatoryaffairs #Blackpharma

Without bioanalysis, personalised medicine would not be possible. The evolving bioanalytical techniques form the cornerstone of drug development and approval in this field. Find out how WuXi AppTec is leading the way in this article in PharmaPhorum. https://hubs.li/Q0322TSf0 #precisionmedicine #innovation #personalisedmedicine

3 of the biggest (but not the only) talking points from our time in the USA this week… Let’s discuss at CPHI info@virtualpharmaalliance.com #pharmalution #evolution #strategy #pharmaceuticals #pharma #productdevelopment #vpa #usa #growth #businessdeveloment #formulation #api #excipient #packaging #medicaldevices #alliances #m&a